Form 4: Intellia Therapeutics Director Brian Goff Reports Acquisition of Shares and Stock Options

Director Brian Goff reports acquisition of 15,409 shares of common stock and 22,297 stock options in Intellia Therapeutics.

Summary

• On June 13, 2024, Brian Goff, a director of Intellia Therapeutics, acquired 15,409 shares of common stock.
• These shares were acquired at a price of $0.00.
• Following this transaction, Goff directly owns 15,409 shares of Intellia Therapeutics common stock.
• Goff also acquired 22,297 stock options with an exercise price of $25.96 on June 13, 2024, expiring on June 12, 2034.
• The stock options vest in installments, starting with 33 1/3% on June 13, 2025, and the remaining 66 2/3% vesting quarterly thereafter.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and options by a director can be seen as a mildly positive signal, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the biotechnology industry.
• Vesting schedules, such as the one described (33 1/3% after one year, then quarterly), are standard practice to incentivize long-term commitment.
• Companies like CRISPR Therapeutics and Editas Medicine also use stock options as part of their compensation packages.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive sign of confidence in the company's future.

Key Dates